Reanalysis of alteplase for stroke stirs controversyBMJ 2004; 329 doi: http://dx.doi.org/10.1136/bmj.329.7470.820-f (Published 07 October 2004) Cite this as: BMJ 2004;329:820
- Jeanne Lenzer
- New York
An independent panel, appointed by a leading US institute to reanalyse the data regarding stroke treatment, has published its findings which they say support the use of thrombolytic agent alteplase (tPA, also known as rt-PA) “to treat patients with acute ischaemic stroke within three hours of onset under the NINDS [National Institute of Neurological Disorders and Stroke] tPA trial protocol.”
Data was reanalysed after an article in the BMJ (2002;324:723-9) sparked off controversy. The original study data reviewed by the panel was published in the New England Journal of Medicine more than nine years ago (1995;333:1581-7).
Critics take issue, however, with the printed conclusions of the analysis published in this month's issue of Stroke (2004;35:2418-24).
Jerome Hoffman, professor of medicine and emergency medicine at the University of California in Los Angeles and a leading critic of calls for widespread use of thrombolysis for stroke, …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial